Tesamorelin Peptide Vial Lyophilisate For Lab Research

BATCH NR: NBLTR3007261101

TESTED FOR:

✓PURITY (HPLC)
✓WEIGHT
✓ENDOTOXINS(LPS)
✓TFA

VIEW LAB REPORTS

Overview

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous growth hormone secretion via pituitary GHRH receptor activation.

In scientific and clinical research contexts, Tesamorelin is primarily studied for its effects on growth hormone (GH) pulsatility, downstream IGF-1 signaling, and metabolic regulation—particularly in relation to visceral adipose tissue modulation.

Unlike shorter experimental peptides, Tesamorelin has been investigated in regulated clinical settings, especially in the context of HIV-associated lipodystrophy.

Mechanism of Action

Tesamorelin acts through the endogenous growth hormone regulatory axis:

1. GHRH Receptor Activation

✓ Binds to growth hormone-releasing hormone receptors in the anterior pituitary
✓ Stimulates pulsatile secretion of endogenous growth hormone
✓ Enhances physiological GH release patterns rather than continuous stimulation

2. IGF-1 Axis Modulation

✓ Increases circulating IGF-1 levels via GH-mediated hepatic signaling
✓ Supports downstream anabolic and metabolic pathways in research and clinical studies
✓ Influences lipid and glucose metabolism indirectly through GH/IGF-1 axis

3. Lipid Metabolism Effects (Clinical Research Focus)

✓ Studied for reduction of visceral adipose tissue (VAT)
✓ Modulates lipid mobilization and fat distribution patterns
✓ Investigated in metabolic syndrome-related models

4. Endocrine Feedback Regulation

✓ Preserves physiological feedback loops of hypothalamic–pituitary axis
✓ Promotes episodic GH secretion rather than constant elevation
✓ Maintains regulatory endocrine signaling dynamics in studied models

Research and Clinical Applications

Tesamorelin has been studied in both clinical and experimental contexts:

Metabolic Research

• Visceral fat reduction mechanisms

• Lipid metabolism regulation

• Insulin sensitivity and glucose homeostasis studies

• Obesity-related endocrine signaling models

Endocrine Research

• Growth hormone pulsatility regulation

• IGF-1 axis modulation

• Pituitary signaling pathway studies

• Hypothalamic–pituitary axis feedback research

HIV-Associated Lipodystrophy (Clinical Context)

• Reduction of visceral adipose tissue in HIV-related metabolic changes

• Body composition normalization studies

• Metabolic complication management research

Aging and Regenerative Research (Experimental Interest)

• Age-related GH decline models

• Body composition changes in aging

• Protein metabolism and lean mass maintenance studies

Technical Specifications

Stability & Storage

Lyophilized Form

• Store at -20°C

• Protect from moisture and light exposure

• Maintain sealed sterile environment

• Avoid repeated freeze-thaw cycles

Reconstituted Solution

• Store at 2–8°C for short-term use

• Limited stability depending on solvent and sterility conditions

• Typically used within defined research or clinical handling windows

• Degradation increases with temperature and microbial exposure

Pharmacokinetic Notes (Research Data)

In studied models:

• Rapid binding to pituitary GHRH receptors after administration

• Induces physiological GH pulsatility rather than sustained elevation

• Secondary increase in IGF-1 with hepatic mediation

• Short plasma half-life but prolonged endocrine downstream effects

Safety and Physiological Considerations (Research Context)

Observed in clinical studies:

• GH/IGF-1 elevation is dose-dependent

• Potential metabolic effects include changes in insulin sensitivity

• Endocrine feedback mechanisms remain active

• Effects are mediated through endogenous hormone systems rather than direct receptor agonism outside GH axis

Research Keywords / PubMed Search Terms

Core Topics

• Tesamorelin GHRH analog

• growth hormone releasing hormone peptide

• GH IGF-1 axis modulation

• pituitary growth hormone secretion

Metabolic Research

• visceral adipose tissue reduction GH

• lipid metabolism growth hormone analog

• insulin sensitivity GH axis

• body composition endocrine regulation

Clinical Context

• HIV-associated lipodystrophy Tesamorelin

• Egrifta (brand context) clinical trials

• visceral fat reduction therapy GH analog

Research Use Only Disclaimer

FOR RESEARCH USE ONLY

This material is intended exclusively for laboratory and scientific research by qualified professionals.

This compound:

• Is not approved for unsupervised human use outside regulated indications

• Is not intended to diagnose, treat, cure, or prevent any disease in this context

• Is not a dietary supplement

• Must only be handled in appropriate clinical or laboratory research environments

All information reflects published scientific and clinical literature. Outcomes observed in studies may vary and are not guaranteed to translate across populations or use cases.

Scientific References

1. Falutz J, Allas S, Blot K, et al.
Metabolic effects of Tesamorelin in HIV-associated lipodystrophy.
New England Journal of Medicine.

2. Stanley TL, Grinspoon SK.
Tesamorelin: growth hormone-releasing hormone analogue.
Expert Opinion on Pharmacotherapy.

3. Falutz J, Mamputu JC, et al.
Long-term safety and efficacy of Tesamorelin.
Journal of Acquired Immune Deficiency Syndromes.